Sep 23, 2013 by Brian Orelli, PhDDrug Development Risk #364: Poorly Run Clinical TrialsThe Food and Drug Administration rejects Merck's anesthesia drug Bridion for the second time.
Sep 20, 2013 by Brian Orelli, PhDThe Good, the Bad, and the Ugly of a Competitor's FailureProsensa's failure isn't all roses for competitor Sarepta.
Sep 19, 2013 by Brian Orelli, PhDMeet the Most Bullish MannKind Investor. Ever.Big hint: He named the company after himself.
Sep 18, 2013 by Brian Orelli, PhDShort High, Buy Low, Break the LawYou can't do it at the same time if you've got inside information.
Sep 18, 2013 by Brian Orelli, PhDApproval? Check. Partner? Not So Much.Dendreon gains EU approval for Provenge, but it needs a partner.
Sep 16, 2013 by Brian Orelli, PhDAn Article About a Press Release About an AdvertisementArena and Eisai start direct-to-consumer advertisements for their obesity drug Belviq.
Sep 10, 2013 by Brian Orelli, PhDA Ringing Endorsement of a Technology Years in the MakingBiogen Idec signs up for more antisense drugs from Isis Pharma.
Sep 3, 2013 by Brian Orelli, PhD2 Reasons This Biotech Hardly Moved After a Successful TrialEsperion's ECT-1002 is better than placebo, but patients have other options; safety may be an issue, too.
Aug 30, 2013 by Brian Orelli, PhDThe Non-FDA Agency That Could Change Drug Development ForeverThe Centers for Medicare & Medicaid Services control what gets paid for.
Aug 30, 2013 by Brian Orelli, PhDThe FDA Loves This DrugAn approval for Pharmacyclics and J&J's ibrutinib seems highly likely
Aug 30, 2013 by Brian Orelli, PhDArena Pharma Pushes ForwardA successful phase 1 trial for pulmonary arterial hypertension treatment APD811.
Aug 30, 2013 by Brian Orelli, PhDIs This a MannKind Killer?We'll know soon enough if Biodel's BIOD-123 has what it takes.
Aug 29, 2013 by Brian Orelli, PhD3 Reasons Why Clinical Trials FailReduce risk by looking out for these common issues.
Aug 29, 2013 by Brian Orelli, PhDThird Obesity Drug Moves Closer to FDA ApprovalOrexigen says its safety trial for Contrave should be completed soon.
Aug 26, 2013 by Brian Orelli, PhDThe Amgen-Onyx Deal Should Make All Biotech Investors HappyM&A is still an option and a lack of over-exuberance means it might continue.
Aug 22, 2013 by Brian Orelli, PhDPop-Worthy Data, Incyte, but Let's See MoreIncyte's phase 2 data leaves questions.
Aug 19, 2013 by Brian Orelli, PhDAttention Biotech Investors: Stop Looking at Share PriceMarket cap is a much better measure of valuation.
